SI4177270T1 - Terapija za raka jajčnikov na osnovi sredstva proti cd47 - Google Patents
Terapija za raka jajčnikov na osnovi sredstva proti cd47Info
- Publication number
- SI4177270T1 SI4177270T1 SI201831145T SI201831145T SI4177270T1 SI 4177270 T1 SI4177270 T1 SI 4177270T1 SI 201831145 T SI201831145 T SI 201831145T SI 201831145 T SI201831145 T SI 201831145T SI 4177270 T1 SI4177270 T1 SI 4177270T1
- Authority
- SI
- Slovenia
- Prior art keywords
- agent
- ovarian cancer
- cancer therapy
- based ovarian
- therapy
- Prior art date
Links
- 206010033128 Ovarian cancer Diseases 0.000 title 1
- 206010061535 Ovarian neoplasm Diseases 0.000 title 1
- 238000011275 oncology therapy Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762573835P | 2017-10-18 | 2017-10-18 | |
| EP22199536.8A EP4177270B1 (en) | 2017-10-18 | 2018-10-18 | Anti-cd47 agent-based ovarian cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI4177270T1 true SI4177270T1 (sl) | 2024-10-30 |
Family
ID=64267915
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201830808T SI3697817T1 (sl) | 2017-10-18 | 2018-10-18 | Terapija za raka jajčnikov na osnovi sredstva proti CD47 |
| SI201831145T SI4177270T1 (sl) | 2017-10-18 | 2018-10-18 | Terapija za raka jajčnikov na osnovi sredstva proti cd47 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201830808T SI3697817T1 (sl) | 2017-10-18 | 2018-10-18 | Terapija za raka jajčnikov na osnovi sredstva proti CD47 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11802153B2 (enExample) |
| EP (2) | EP4177270B1 (enExample) |
| JP (2) | JP7308191B2 (enExample) |
| KR (1) | KR102776457B1 (enExample) |
| CN (2) | CN117771364A (enExample) |
| AU (1) | AU2018351006B2 (enExample) |
| CA (1) | CA3078253A1 (enExample) |
| ES (2) | ES2989007T3 (enExample) |
| PL (2) | PL3697817T3 (enExample) |
| PT (2) | PT4177270T (enExample) |
| SI (2) | SI3697817T1 (enExample) |
| WO (1) | WO2019079548A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2796378T3 (es) | 2016-01-11 | 2020-11-26 | Forty Seven Inc | Anticuerpos monoclonales anti-cd47 humanizados, de ratón o químicos |
| US11802153B2 (en) | 2017-10-18 | 2023-10-31 | Forty Seven, Inc. | Anti-CD47 agent-based ovarian cancer therapy |
| EP4129336B1 (en) | 2018-02-12 | 2025-05-07 | Forty Seven, LLC | Anti-cd47 agent-based treatment of cd20-positive cancer |
| CA3111323A1 (en) | 2018-09-04 | 2020-03-12 | Trillium Therapeutics Inc. | Cd47 blockade with parp inhibition for disease treatment |
| AU2020410410A1 (en) | 2019-12-17 | 2022-06-09 | Pfizer Inc. | Antibodies specific for CD47, PD-L1, and uses thereof |
| CN115361971A (zh) * | 2020-04-06 | 2022-11-18 | 里兰斯坦福初级大学理事会 | 抗体制剂 |
| JP2023530499A (ja) * | 2020-06-22 | 2023-07-18 | モルフォシス・アーゲー | 抗ＣＤ１９抗体及びＳＩＲＰα－ＣＤ４７自然免疫チェックポイントを遮断するポリペプチドを含む抗腫瘍組み合わせ療法 |
| WO2022171121A1 (zh) * | 2021-02-10 | 2022-08-18 | 同润生物医药(上海)有限公司 | 治疗肿瘤的方法和组合 |
| CA3193664A1 (en) * | 2021-04-14 | 2022-10-20 | Akeso Biopharma, Inc. | Anti-cd47 monoclonal antibody and use thereof |
| KR20240019111A (ko) * | 2021-06-10 | 2024-02-14 | 오노 야꾸힝 고교 가부시키가이샤 | Cd47 저해 물질, 면역 체크포인트 저해 물질 및 표준 요법의 병용에 의한 암 치료법 |
| CN115245516A (zh) * | 2021-12-31 | 2022-10-28 | 郑州大学第一附属医院 | 一种抗卵巢癌肿瘤药物联用方法、体外和体内验证方法 |
| US20250228938A1 (en) * | 2022-03-08 | 2025-07-17 | Whitehead Institute For Biomedical Research | The combination of macrophage-directed immunotherapy and targeted agents for treatment of cancer |
| TWI876305B (zh) * | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2735144T3 (es) | 2008-01-15 | 2019-12-16 | Univ Leland Stanford Junior | Métodos para manipular fagocitosis mediada por CD47 |
| US20160095939A1 (en) | 2014-10-07 | 2016-04-07 | Immunomedics, Inc. | Neoadjuvant use of antibody-drug conjugates |
| US8758750B2 (en) | 2009-09-15 | 2014-06-24 | The Board Of Trustees Of The Leland Stanford Junior University | Synergistic anti-CD47 therapy for hematologic cancers |
| WO2011041453A1 (en) | 2009-09-29 | 2011-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Isolation and use of melanoma cancer stem cells |
| JP6166177B2 (ja) | 2010-05-14 | 2017-07-19 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Ｃｄ４７に対するヒト化及びキメラモノクローナル抗体 |
| WO2012088309A1 (en) | 2010-12-21 | 2012-06-28 | The Board Of Trustees Of The Leland Stanford Junior University | Therapeutic and diagnostic methods for manipulating phagocytosis through calreticulin and low density lipoprotein-related receptor |
| SMT202000689T1 (it) | 2012-01-17 | 2021-01-05 | Univ Leland Stanford Junior | Reagenti per sirp-alfa ad alta affinita' |
| BR112015013431A2 (pt) * | 2012-12-12 | 2017-11-14 | Vasculox Inc | anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos |
| ES2728066T3 (es) | 2013-03-15 | 2019-10-22 | Univ Leland Stanford Junior | Métodos para la obtención de dosis terapéuticamente eficaces de agentes anti-CD47 |
| JP6843611B2 (ja) | 2013-04-29 | 2021-03-17 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 免疫を強化する抗ｃｄ４７因子の使用 |
| US9945870B2 (en) | 2013-05-17 | 2018-04-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for determining responsiveness to an anti-CD47 agent |
| EP3116544A4 (en) | 2014-03-11 | 2017-08-23 | The Board of Trustees of the Leland Stanford Junior University | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
| WO2016023001A1 (en) | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Multispecific high affinity pd-1 agents and methods of use |
| ES2819451T3 (es) | 2014-08-08 | 2021-04-16 | Univ Leland Stanford Junior | Agentes PD-1 de alta afinidad y procedimientos de uso |
| EP3209769B1 (en) | 2014-10-24 | 2020-08-05 | The Board of Trustees of the Leland Stanford Junior University | Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| AU2016209268B2 (en) | 2015-01-21 | 2021-04-29 | The Board Of Trustees Of The Leland Stanford Junior University | Macrophages eat cancer cells using their own calreticulin as a guide |
| US10358472B2 (en) | 2015-05-06 | 2019-07-23 | The Board Of Trustees Of The Leland Stanford Junior University | High affinity CD47 analogs |
| US20180147257A1 (en) | 2015-05-22 | 2018-05-31 | The Board Of Trustees Of The Leland Stanford Junior University | Btn3a ectodomain proteins and methods of use |
| WO2017019767A1 (en) | 2015-07-27 | 2017-02-02 | Myosotis, Llc | Inhibition of CXCL12 in Cancer Immunotherapy |
| SI3341015T2 (sl) | 2015-08-26 | 2024-03-29 | The Board Of Trustees Of The Leland Stanford, Junior University | Izboljšana deplecija ciljanih celic z blokado CD47 in imunostimulatornim agonistom |
| WO2017049251A2 (en) * | 2015-09-18 | 2017-03-23 | Tioma Therapeutics, Inc. | Therapeutic cd47 antibodies |
| US10344094B2 (en) * | 2015-12-11 | 2019-07-09 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cancer with dual targeting of CD47 and EGFR |
| BR112018013094A2 (pt) | 2015-12-28 | 2018-12-11 | Merck Patent Gmbh | combinação de inibidor de hdac e anticorpo de anti-pd-l1 para o tratamento de câncer ovariano |
| ES2796378T3 (es) | 2016-01-11 | 2020-11-26 | Forty Seven Inc | Anticuerpos monoclonales anti-cd47 humanizados, de ratón o químicos |
| CN109071676A (zh) * | 2016-01-21 | 2018-12-21 | 小利兰·斯坦福大学托管委员会 | 使用免疫调节剂的组合的癌症治疗 |
| PL3442578T3 (pl) | 2016-04-15 | 2022-06-20 | The Board Of Trustees Of The Leland Stanford Junior University | Sposoby określania i osiągania terapeutycznie skutecznych dawek środków anty-cd47 w leczeniu nowotworów |
| US10611842B2 (en) | 2016-08-03 | 2020-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRPα antibody therapy |
| WO2018031419A1 (en) | 2016-08-12 | 2018-02-15 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for enhancing immunogenic cross-presentation of tumor antigens |
| WO2018081448A1 (en) | 2016-10-26 | 2018-05-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
| WO2018165015A1 (en) | 2017-03-09 | 2018-09-13 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of pediatric brain tumors with targeting of cd47 pathway |
| US11802153B2 (en) | 2017-10-18 | 2023-10-31 | Forty Seven, Inc. | Anti-CD47 agent-based ovarian cancer therapy |
| EP4194470A1 (en) | 2017-10-18 | 2023-06-14 | Forty Seven, Inc. | Treatment of ovarian cancer with anti-cd47 and anti-pd-l1 |
| EP3807319A4 (en) | 2018-06-13 | 2022-05-25 | The Board of Trustees of the Leland Stanford Junior University | Compositions and methods for inducing phagocytosis |
| WO2020068431A1 (en) | 2018-09-28 | 2020-04-02 | The Board Of Trustees Of The Leland Stanford Junior University | Analysis of polymorphisms in sirp-alpha for evaluating response to immunotherapy |
| WO2020160285A1 (en) | 2019-02-01 | 2020-08-06 | The Board Of Trustees Of The Leland Stanford Junior University | SIRPα EXPRESSION ON T CELLS IS A BIOMARKER FOR FUNCTIONAL T CELLS DURING EXHAUSTION |
| WO2020163692A1 (en) | 2019-02-08 | 2020-08-13 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cutaneous t cell lymphoma with targeting of cd47 pathway |
-
2018
- 2018-10-18 US US16/756,673 patent/US11802153B2/en active Active
- 2018-10-18 CA CA3078253A patent/CA3078253A1/en active Pending
- 2018-10-18 WO PCT/US2018/056441 patent/WO2019079548A1/en not_active Ceased
- 2018-10-18 KR KR1020207014145A patent/KR102776457B1/ko active Active
- 2018-10-18 SI SI201830808T patent/SI3697817T1/sl unknown
- 2018-10-18 EP EP22199536.8A patent/EP4177270B1/en active Active
- 2018-10-18 JP JP2020522016A patent/JP7308191B2/ja active Active
- 2018-10-18 PT PT221995368T patent/PT4177270T/pt unknown
- 2018-10-18 PL PL18800381.8T patent/PL3697817T3/pl unknown
- 2018-10-18 ES ES22199536T patent/ES2989007T3/es active Active
- 2018-10-18 AU AU2018351006A patent/AU2018351006B2/en active Active
- 2018-10-18 CN CN202311510416.3A patent/CN117771364A/zh active Pending
- 2018-10-18 PT PT188003818T patent/PT3697817T/pt unknown
- 2018-10-18 ES ES18800381T patent/ES2932286T3/es active Active
- 2018-10-18 CN CN201880068424.8A patent/CN111247172B/zh active Active
- 2018-10-18 SI SI201831145T patent/SI4177270T1/sl unknown
- 2018-10-18 EP EP18800381.8A patent/EP3697817B1/en active Active
- 2018-10-18 PL PL22199536.8T patent/PL4177270T3/pl unknown
-
2022
- 2022-11-22 JP JP2022186406A patent/JP2023018062A/ja active Pending
-
2023
- 2023-09-27 US US18/373,655 patent/US20240150461A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200283520A1 (en) | 2020-09-10 |
| ES2932286T3 (es) | 2023-01-17 |
| CA3078253A1 (en) | 2019-04-25 |
| JP2023018062A (ja) | 2023-02-07 |
| CN117771364A (zh) | 2024-03-29 |
| KR20200068730A (ko) | 2020-06-15 |
| US11802153B2 (en) | 2023-10-31 |
| PT4177270T (pt) | 2024-10-23 |
| EP4177270B1 (en) | 2024-07-31 |
| JP7308191B2 (ja) | 2023-07-13 |
| CN111247172B (zh) | 2023-11-14 |
| PT3697817T (pt) | 2023-01-02 |
| SI3697817T1 (sl) | 2023-01-31 |
| PL3697817T3 (pl) | 2023-01-23 |
| AU2018351006A1 (en) | 2020-05-07 |
| EP3697817B1 (en) | 2022-10-05 |
| ES2989007T3 (es) | 2024-11-25 |
| EP3697817A1 (en) | 2020-08-26 |
| AU2018351006B2 (en) | 2024-08-29 |
| KR102776457B1 (ko) | 2025-03-06 |
| CN111247172A (zh) | 2020-06-05 |
| US20240150461A1 (en) | 2024-05-09 |
| PL4177270T3 (pl) | 2024-11-18 |
| JP2021500349A (ja) | 2021-01-07 |
| WO2019079548A1 (en) | 2019-04-25 |
| EP4177270A1 (en) | 2023-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3697817T1 (sl) | Terapija za raka jajčnikov na osnovi sredstva proti CD47 | |
| IL271946A (en) | Combination for cancer treatment | |
| GB201707153D0 (en) | Therapy | |
| LT3197456T (lt) | Vėžio gydymas | |
| PT3576740T (pt) | Tratamento de cancro | |
| GB201719646D0 (en) | Therapy | |
| GB201708663D0 (en) | Therapy | |
| DK3292140T3 (en) | Immunterapeutikum mod cancer | |
| SG10202105110VA (en) | Cancer treatment | |
| GB201706451D0 (en) | Cancer treatment | |
| IL274626A (en) | Cancer treatment | |
| GB201519331D0 (en) | Treatment paradigm | |
| IL260814A (en) | Cancer treatment | |
| GB201707864D0 (en) | Platinum-reistant cancer treatment | |
| GB201519734D0 (en) | Cancer therapy | |
| GB201522433D0 (en) | Cancer treatment | |
| GB201704909D0 (en) | Cancer therapy | |
| GB201707500D0 (en) | New therapy | |
| GB201711855D0 (en) | Cancer therapy | |
| HK40037091A (en) | Gp96-based cancer therapy | |
| GB201711250D0 (en) | Cancer therapy | |
| GB201710198D0 (en) | Cancer therapy | |
| GB201706046D0 (en) | Cancer therapy | |
| HK40009559A (en) | Anti-cd47 combination therapy | |
| GB201700772D0 (en) | Cancer therapy |